Psychiatric Adverse Effects Of Interferon Therapy.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or meta-analytic data synthesis
What was done
This narrative review summarizes clinical literature regarding psychiatric adverse effects resulting from immunomodulating interferon therapy, their clinical presentation, timing of onset, and management strategies.
What was found
The abstract reports no quantitative data, incidence rates, or statistical effect sizes. It notes that interferon therapy is linked to diverse psychiatric symptoms—including depression, suicidal behavior, manic syndrome, anxiety, psychosis, delirium, fatigue, irritability, psychomotor retardation, decreased libido, insomnia, and cognitive deficits—and can worsen pre-existing psychiatric conditions, with most adverse events emerging after three weeks of treatment.
Why it matters
Understanding the spectrum and typical onset of interferon-induced psychiatric symptoms can improve multidisciplinary psychiatric management, potentially preventing the unnecessary exclusion of high-risk patients with mood or substance use disorders from treatment.
Limits
As a narrative review, the paper lacks systematic search criteria, quality assessment, and pooled quantitative data. The abstract notes that primary studies with statistically significant sample sizes are relatively few.
Cited by
- partial In the early 1970s, using gamma interferon as a cancer therapy caused treated patients to develop psychosis.